Electronic Supplementary Material (ESI) for Nanoscale.

Encapsulation of 4-Oxo-N-(4-hydroxyphenyl) Retinamide in Human Serum Albumin Nanoparticles Promotes EZH2 Degradation in preclinical Neuroblastoma models

Boddu Mrunalini,[a] Atul Dev,[a] Avinash Chandra Kushwaha,[a] Mohammed Nadim Sardoiwala,[a] and Surajit Karmakar *[a]



Figure S1. Morphological characterization of (a) & (b) HSANPs; (c) & (d) 4O4HPR loaded HSANPs by Field Emission Scanning Electron Microscope showing the spherical morphology of the nanoformulations.



Figure S2: (a) Stability profile for hydrodynamic size of 4O4HPR loaded HSANPs in PBS with varying pH 7.4, 6.4, 5.4, 4.4, 10% DMEM, 2% DMEM and Incomplete DMEM; (b) Standard curve of 4O4HPR



Figure S3. Flow cytometric analysis of rhodamine-tagged 4O4HPR loaded HSANPs compared to HSANPs demonstrates the higher uptake percentage of 4O4HPR loaded HSANPs.



Figure S4. Drug release kinetics from (a) & (b) 4O4HPR (c) & (d) 4O4HPR loaded HSANPs in PBS-7.4.



Figure S5. Cell viability assay for the dose optimization of MG132 for proteasomal pathway inhibitor study in SH-SY5Y cells treated with a high dose of MG132 for 3 hours followed by 4O4HPR loaded HSANPs treatment; (n = 3), where n is number of experimental repeats.

Supplementary Table

GAPDH	Forward primer	5`-GACTCATGACCACAGTCCATGC-3`
	Reverse primer	5`-AGAGGCAGGGATGATGTTCTG-3`
PKC-δ	Forward primer	5`-AAAGGCAGCTTCGGGAAGGT-3`
	Reverse primer	5`-TGGATGTGGTACATCAGGTC-3`
EzH2	Forward primer	5'-GCCAGACTGGGAAGAAATCTG-3’
	Reverse primer	5’-TGTGCTGGAAAATCCAAGTCA-3’

Supplementary Table 1. List of primers used for quantitative PCR analysis.